STERIS (NYSE:STE) Receives “Hold” Rating from Needham & Company LLC

STERIS (NYSE:STE)‘s stock had its “hold” rating restated by stock analysts at Needham & Company LLC in a research note issued to investors on Monday,Benzinga reports.

Several other equities research analysts have also commented on STE. JMP Securities restated a “market outperform” rating and set a $265.00 target price on shares of STERIS in a research report on Thursday, February 6th. Piper Sandler raised their price objective on shares of STERIS from $260.00 to $265.00 and gave the company an “overweight” rating in a research note on Monday, February 3rd. Finally, Stephens restated an “overweight” rating and set a $240.00 target price on shares of STERIS in a research report on Thursday, February 6th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $258.75.

STERIS Trading Down 2.1 %

NYSE STE opened at $208.26 on Monday. The company has a quick ratio of 1.40, a current ratio of 2.13 and a debt-to-equity ratio of 0.32. The stock has a market capitalization of $20.46 billion, a P/E ratio of 44.22 and a beta of 0.87. STERIS has a 52-week low of $197.82 and a 52-week high of $248.24. The firm has a 50-day moving average price of $222.54 and a 200 day moving average price of $219.97.

STERIS (NYSE:STE) last issued its earnings results on Wednesday, February 5th. The medical equipment provider reported $2.32 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.33 by ($0.01). STERIS had a return on equity of 13.91% and a net margin of 8.66%. Equities research analysts expect that STERIS will post 9.08 EPS for the current year.

Institutional Investors Weigh In On STERIS

Several institutional investors and hedge funds have recently made changes to their positions in STE. Avalon Trust Co acquired a new position in STERIS during the fourth quarter worth about $30,000. Human Investing LLC purchased a new position in shares of STERIS during the 4th quarter worth approximately $31,000. Anfield Capital Management LLC raised its position in shares of STERIS by 100.0% during the 4th quarter. Anfield Capital Management LLC now owns 182 shares of the medical equipment provider’s stock worth $37,000 after purchasing an additional 91 shares during the last quarter. Central Pacific Bank Trust Division lifted its stake in STERIS by 65.5% in the 4th quarter. Central Pacific Bank Trust Division now owns 192 shares of the medical equipment provider’s stock valued at $39,000 after buying an additional 76 shares in the last quarter. Finally, Manchester Capital Management LLC grew its holdings in STERIS by 182.7% during the 4th quarter. Manchester Capital Management LLC now owns 212 shares of the medical equipment provider’s stock valued at $44,000 after buying an additional 137 shares during the last quarter. 94.69% of the stock is currently owned by hedge funds and other institutional investors.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.